{
  "name" : "dacemirror.sci-hub.se_journal-article_1599735a70c152c1275fcd204bc1440d_dhaun2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Endothelins in cardiovascular biology and therapeutics",
    "authors" : [ ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "Following the identification of a vasoconstrictor peptide in the culture media of bovine aortic endothelial cells in 1985 (ref.1), Yanagisawa and colleagues2 moved rapidly to identify the structure of a vasoconstrictor peptide of 21 amino acids in length named endothelin. The researchers showed endothelin to be an extremely potent vasoconstrictor with uniquely long-lasting effects. Additionally, the investigators used cloning and sequencing to show that what we now know as endothelin 1 (ET-1) is generated through unusual proteolytic processing to produce the mature peptide from an inactive precursor, big endothelin, by the action of a putative endothelin-converting enzyme (ECE), providing a potential route to inhibit ET-1 generation and actions (fig. 1). Yanagisawa and co-workers also recognized that ET-1 might be important in regulating basal vascular tone and that the actions of ET-1 might contribute to the pathogenesis of hypertension and vascular spasm.\nIn this Review, we address the cardiovascular biology of the endothelin system, focusing on those aspects that are relevant to human disease. We also discuss the current understanding of where targeting the endothelin system, in a range of cardiovascular and renal diseases, offers therapeutic benefit or is worthy of further investigation."
    }, {
      "heading" : "The endothelin system",
      "text" : "Biology. Three endothelin peptides (ET-1, ET-2 and ET-3) with two unique cysteine–cysteine crosslinks, two ECEs (ECE1 and ECE2) and two mammalian G protein-coupled receptors (endothelin receptor type A (ETA) and endothelin receptor type B (ETB)) have now been identified. ET-1 is the most abundant endothelin isoform in the human cardiovascular system and is, therefore, the focus of this Review. Although generated in many organs, including the heart and kidneys, the major source of ET-1 is the vascular endothelium, where ET-1 is continuously generated in blood vessels to maintain vascular tone3 and blood pressure (BP)4. ET-1 is largely secreted abluminally, towards the vascular smooth muscle, with picomolar levels in the blood, largely reflecting the action of ET-1 as a local hormone with overspill into the circulation. Elevation of plasma ET-1 levels is a marker of ETB antagonism5, so raised levels in disease states might relate to either increased production or reduced clearance.\nThe major sites of EDNRA (encoding ETA) mRNA expression are the vasculature, heart, lungs, ovaries and uterus, whereas EDNRB (encoding ETB) mRNA is mainly expressed in the brain and lungs6 (fig. 2). From a combination of knockout, overexpression and pharmacological studies in health and disease6, we now know\n1University of Edinburgh/ British Heart Foundation Centre of Research Excellence, Centre for Cardiovascular Science, Queen’s Medical Research Institute, Edinburgh, UK. 2Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.\n*e-mail: bean.dhaun@ ed.ac.uk\nhttps://doi.org/10.1038/ s41569-019-0176-3\nNature reviews | Cardiology\nthat the major vascular actions of ET-1 on vascular smooth muscle ETA are to promote vasoconstriction, hypertension, hypertrophy, fibrosis and inflammatory changes, including atherosclerosis (Tables 1,2). By contrast, endothelial ETB stimulates local nitric oxide (NO) production and clears ET-1 from the circulation. Importantly, ETB in the collecting ducts of the kidneys seems to have an important role in promoting natriuresis7. However, the situation is not straightforward because ETB on vascular smooth muscle can promote vasoconstriction and might have a more prominent role in conditions such as systemic and pulmonary arterial hypertension (PAH) and also contribute to adrenal generation of aldosterone (Tables 1,2). An interesting and important study showed that a common non-coding gene sequence variant in chromosome 6 regulates the expression of EDN1 (encoding ET-1) and is linked to five common vascular conditions: coronary artery disease, hypertension, migraine, cervical artery dissection and fibromuscular hyperplasia8.\nEndothelin receptor antagonists. Early work led to the creation of the mixed ETA/ETB antagonist bosentan, and additional medicinal chemistry has generated a range of other small-molecule endothelin receptor antagonists (ERAs)9 that either selectively inhibit ETA or inhibit both ETA and ETB (Table 3). In addition, BQ123 (a peptide ETA antagonist) and BQ788 (a peptide ETB antagonist) were critical in determining the physiological and pathological role of ET-1 in cardiovascular disease. On the basis of the actions of ET-1, early clinical research programmes with ERAs focused on hypertension, heart failure, subarachnoid haemorrhage and PAH, resulting in an orphan indication for PAH for bosentan and, subsequently, for ambrisentan and macitentan. Other research has focused on the actions of ET-1 in kidney disease, pain syndromes and sickle cell disease.\nDevelopment of ECE inhibitors has been disappointing and, even when combined as dual inhibitors of ECE and neutral endopeptidase (also known as neprilysin), has not made it further than preliminary studies in the clinic. An alternative approach, suggested by the sulfonamide scaffold present in bosentan9, has generated\nsparsentan, the first and only current agent combining an ERA with angiotensin receptor-blocking properties. Opportunities exist to develop further ERAs with non-sulfonamide structures or by exploiting biased signalling, both of which might limit adverse effects.\nOn the basis of what is known from animal studies about the developmental role of ET-1, ERAs will be first-trimester teratogens. These agents are, therefore, used in women of reproductive age only when conception can be prevented. As a result of on-target effects of ET-1, ERAs can cause vasodilator effects such as flushing, headache and hypotension or faintness. ERAs also cause a reversible reduction in blood haemoglobin level and cause fluid retention and dependent oedema, probably though plasma expansion and altered Starling capillary forces. Sulfonamide structures, such as those that occur in bosentan, are known to cause hepatic transaminitis, and the ERA sitaxentan was withdrawn after the drug was found to cause severe liver failure. However, this adverse effect is not a uniform problem of ERAs because liver dysfunction is not seen, for instance, with ambrisentan, a propionic acid derivative, nor with atrasentan, another agent without a sulfonamide scaffold9. These issues were borne out by a meta-analysis10 that identified hepatic transaminitis, peripheral oedema and anaemia as the main adverse effects of treatment with ERAs. Perhaps the most clinically challenging ongoing problem with the use of ERAs is fluid retention, which in hypertension has proved manageable with up-titration of existing diuretics or use of additional diuretics."
    }, {
      "heading" : "Hypertension",
      "text" : "Yanagisawa and colleagues first identified the longlasting vasoconstrictor and pressor actions of ET-1 and predicted that ET-1 might be important in the control of systemic BP and contribute to the pathogenesis of hypertension2. This finding was followed by evidence showing that vascular production of ET-1 is increased in many (salt-sensitive) animal models of hypertension11 and that BP could be lowered by endothelin-blocking agents in these models12. In patients with hypertension, some evidence indicates that resistance vessels might be particularly sensitive to ERAs and that plasma ET-1 levels are elevated, but these data are inconsistent6.\nGiven its global primacy as a risk factor for cardiovascular disease13, hypertension was unsurprisingly one of the first targets for the dual antagonist bosentan14. Indeed, in a randomized, controlled trial in patients with primary hypertension and a diastolic BP of 95–115 mmHg, bosentan (100–2,000 mg once daily) was shown to reduce clinic BP by 6 mmHg compared with placebo, similar to the effect of the angiotensin-converting enzyme inhibitor enalapril (20 mg once daily)14. However, some cases of liver dysfunction and fluid retention occurred at these doses, influencing the balance of benefit to harm, and bosentan was subsequently successfully developed at lower doses for use in patients with PAH. These encouraging observations were confirmed with the modestly ETA-selective antagonist darusentan (10 mg, 30 mg or 100 mg daily), which reduced BP by ~10 mmHg at the highest dose and sustained the reduction after 6 weeks of treatment15.\nKey points\n• Endothelin 1 (ET-1) is the most potent endogenous vasoconstrictor and contributes to basal vascular tone as well as a number of diseases, such as hypertension, chronic kidney disease (CKD), pulmonary arterial hypertension (PAH) and pre-eclampsia.\n• A common non-coding gene sequence variant regulates the expression of EDN1 (encoding ET-1) and is linked to five common vascular conditions: coronary artery disease, hypertension, migraine, cervical artery dissection and fibromuscular hyperplasia.\n• The effects of ET-1 are mediated via two G protein-coupled receptors, endothelin receptor type A (ETA) and endothelin receptor type B (ETB); selective ETA and dual ETA/ETB receptor antagonists (endothelin receptor antagonists; ERAs) are available for clinical use.\n• The phase III PRECISION study will explore the use of a long-acting, selective ETA antagonist in treatment-resistant hypertension.\n• For many patients with PAH, ERAs are considered first-line treatment; ERAs also reduce blood pressure and proteinuria in CKD and show clinical potential in scleroderma renal crisis, the transition from acute kidney injury to CKD and end-stage renal disease.\nwww.nature.com/nrcardio\nGiven the range of established treatments for uncomp licated primary hypertension, the focus has moved to treatment-resistant hypertension, in which BP is uncontrolled despite taking three or more agents of different classes at optimal doses, including a diuretic. This condition is estimated to affect 10 million people globally. Importantly, this group of patients is at high risk of having comorbidities and a poor outcome16. Early data suggested a role for the endothelin system in treatment-resistant hypertension17. On this basis, darusentan was studied in two major randomized, placebo-controlled trials. The DORADO trial18, published in 2009, was undertaken in 379 patients with treatment-resistant hypertension and showed that darusentan at doses of 50 mg, 100 mg or 300 mg daily reduced the co-primary end points of seated systolic/ diastolic BP at week 14 of treatment by 17/10 mmHg, 18/10 mmHg and 18/11 mmHg, respectively, which was significantly greater than the reductions with placebo (9/5 mmHg). The benefits were seen in all groups of patients, including those with type 2 diabetes mellitus and/or chronic kidney disease (CKD). The only major adverse effect of darusentan was fluid retention, occurring in ~25% of patients receiving darusentan (and only ~14% of those receiving placebo). These results were nonetheless promising, and fluid retention seemed to be manageable by increasing the dose of diuretics without withdrawing patients from the study. A further study, the DORADO-AC trial19, this time with an active control, was undertaken for licensing purposes and included 1,453 patients with treatmentresistant hypertension. The darusentan doses used were the same as those in the DORADO trial, as were the duration of treatment and the co-primary end point. The active control (guanfacine 1 mg daily) was an unusual choice and unfamiliar to most physicians for this indication. Seated systolic/diastolic BP at week 14 was reduced by 15/10 mmHg with darusentan, which was significantly more than the reduction with guanfacine (12/6 mmHg). However, the placebo unexpectedly reduced BP by 14/8 mmHg at 14 weeks. This response was not different from that with darusentan for systolic BP and was greater than that with guanfacine for diastolic BP. Although darusentan was well tolerated and outperformed both placebo and guanfacine, in a post hoc, time-weighted analysis and on the basis of ambu latory BP monitoring (challenging the wisdom of using clinic BP measurements in major hypertension trials20), darusentan did not meet its\nPhysicochemical stimuli • Hypoxia • Shear stress\n(low) • Acidosis\nBlood components • Glucose • Thrombin • Oxidized\nLDL\nHormones • Adrenaline • Angiotensin II • Vasopressin • Insulin • Cortisol Peptides • Cytokines • IL-1 • TGFβ • ET-1 • Endotoxin Inhibition • Prostacyclin • Nitric oxide • ANP and BNP • Heparin • Shear stress\n(high)\nPromoter EDN1 gene\nPrepro-EDN1 mRNA\nPrepro-ET-1 C-terminal fragment\nBig ET-1\nRelaxationContraction\nFurin\nECE\nET B\nET B\nET B\nET A\nNitric oxide ProstaglandinsLysosomal degradation Endothelial clearing receptors in kidneys and lungs\nVascular smooth muscle cell\n+ + + + –\nNucleus\nEndothelial cell\nCys\nCys His LeuCys\nSer SerSerLeu\nAsp\nAsp\nIIe IIe Trp\nVal\nAsn Thr Glu His Val Val\nSer Arg Pro\nProPro\nSer\nTyr\nGly\nGly\nLeu Lys Glu Cys Val Tyr\nPhe Met\nCOOH\nCOOH\nCOOH\nNH 2\nNH 2\nNH 2\nBig ET-1\nCys\nCys His LeuCys\nSer SerSerLeu\nAsp\nAsp\nIIe IIe Trp\nLys Glu Cys Val Tyr\nPhe Met\nET-1\nK–R R–R\n5′ 3′Coding regionmRNA AUUUA-3′ UTR\nFurin PC7 convertases\nECE2 pH 5.5\nECE1 pH 7\nNeutral endopeptidase\nDegraded ET-1ET-1\nET-1\nPrepro-ET-1\nFig. 1 | Endothelin 1 synthesis and sites of action. A schematic of the regulators of endothelin 1 (ET-1) synthesis, the pathway for ET-1 generation (inset) and the sites of ET-1 action (bottom) is shown. ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; ECE, endothelin-converting enzyme; ETA, endothelin receptor type A ; ETB, endothelin receptor type B; TGFβ, transforming growth factor-β; UTR , untranslated region.\nNature reviews | Cardiology\nprespecified co-primary end points, and this agent has not been further developed for patients with treatment-resistant hypertension.\nA UK study in treatment-resistant hypertension21 showed the clear superiority of the mineralocorticoid receptor antagonist spironolactone (25–50 mg daily) over the α-blocker doxazosin (4–8 mg daily) and the β-blocker bisoprolol (5–10 mg daily). Although used off-label, the evidence in support of spironolactone is strong. However, spironolactone can cause hyperkalaemia, and gynaecomastia can be a problem in men, so a need remains for an effective, well-tolerated and licensed therapy for treatment-resistant hypertension.\nIn this regard, Idorsia has announced the encouraging results of a phase II study with aprocitentan, the active metabolite of the ERA macitentan22. In this study, 490 patients with primary hypertension were randomly assigned to receive aprocitentan (5 mg, 10 mg, 25 mg or 50 mg), placebo or lisinopril (20 mg) once daily. In a report published by Idorsia, the study showed (in a per-protocol analysis) a dose-dependent reduction of 6–12 mmHg in diastolic BP with aprocitentan, compared with reductions of 5 mmHg and 8 mmHg for placebo and lisinopril, respectively23. Systolic BP reductions ranged from 10.0 mmHg to 18.5 mmHg with aprocitentan\nand were 8 mmHg and 13 mmHg for placebo and lisinopril, respectively. These findings were confirmed in an intention-to-treat analysis and by 24 h ambulatory BP monitoring. As a result of these encouraging data, Idorsia has launched a phase III trial, the PRECISION study24, in treatment-resistant hypertension, providing some optimism that a licensed agent for the treatment of treatment-resistant hypertension might emerge from our understanding of endothelin biology. In the treatment of a chronic, asymptomatic risk factors for cardiovascular disease, such as hypertension, poor adherence is a substantial problem. In these circumstances, agents with a half-life of ≥12 h (Table 3) have the benefit that they need to be taken only once daily. Aprocitentan has a particularly long half-life, which can also compensate for poor adherence associated with the occasional missed dose.\nWhether the reduction in blood haemoglobin level that is seen with ERAs is a major issue is unresolved (no evidence is currently available). The frequency of fluid retention is also uncertain, as is the ease with which treatment-resistant hypertension can be managed in patients who are already taking diuretics (although fluid retention was uncommon in the phase II study with aprocitentan). ETA selectivity does not seem to be a clear\nC er\neb el\nlu m\nBr ai\nns te m H yp ot ha la\nm us\nC er\neb ra\nl c or\nte x\nH ip\npo ca\nm pu s St ri at um O lfa ct or y bu lb\nO lfa\nct or\ny ep\nit he\nliu m\nRe ti na W ho le e ye\nPi tu\nit ar\ny gl\nan d\nIs le\nts o\nf L an\nge rh\nan s\nA dr\nen al\ng la nd Th yr oi d/ pa ra th yr oi d A or ta V en a ca va H ea rt a tr iu m H ea rt v en tr ic le Lu ng Tr ac he a\nBr ow\nn ad\nip os\ne ti\nss ue\nW hi\nte a\ndi po\nse ti\nss ue\nA di\npo cy\nte Li ve r\nSk el\net al\nm us\ncl e\nKi dn ey Pa nc re as G al l b la dd er La rg e in te st in e Sm al l i nt es ti ne St om ac h\nU ri\nna ry\nb la\ndd er\nO va ry Te st es U te ru s To ng ue O es op ha gu s Sk in Sp le en Th ym us Bo ne m ar ro w\n2,000\n1,000\n1,500\n3,000\n4,500\n0\n0\nEd nr\na re\nla ti\nve e\nxp re\nss io n Ed nr b re la ti ve e xp re ss io n\na\nb\nFig. 2 | Endothelin receptor mrNa expression in different organs. Graphs of the relative expression of Ednra mRNA (encoding the endothelin receptor type A ; part a) and Ednrb mRNA (encoding the endothelin receptor type B; part b) in 41 adult mouse tissues are shown (mean ± s.e.m.). High expression of Ednra mRNA is found in cardiovascular and pulmonary tissues, whereas high expression of Ednrb mRNA is found in brain tissues (boxes). Reproduced from ref.6,\nCC-BY-4.0 https://creativecommons.org/licenses/by/4.0/.\nwww.nature.com/nrcardio\nbenefit because even very selective agents can cause fluid retention25, and no evidence is available that fluid retention is more frequent with dual antagonists. Research, albeit from the manufacturers of aprocitentan, even suggests that dual ERAs might be protective against fluid retention26. The PRECISION trial might also provide an opportunity to explore whether biomarkers exist, such as plasma ET-1 level or particular gene variants8, that can be used to select the patients who are most likely to respond to therapy."
    }, {
      "heading" : "Heart failure",
      "text" : "Chronic heart failure (CHF) was one of the earliest indications explored for ERAs. This approach was underpinned by compelling preclinical studies showing increased myocardial expression of ET-1 in experimental CHF and improvement in myocardial function and survival with BQ-123 treatment in rats27,28. In human studies, investigators showed that higher levels of plasma ET-1 in CHF were associated with more severe disease29. Short-term intravenous administration of bosentan30 or BQ-123 (ref.31) reduced systemic and pulmonary vascular resistance and BP, whereas cardiac index increased. These promising effects were not associated with changes in heart rate, and only one case of symptomatic hypotension occurred.\nThese encouraging data prompted a number of companies to pursue programmes of CHF treatment with ERAs, and four large, multicentre, randomized, controlled trials were initiated. Unfortunately, none was successful32. The REACH-1 trial with bosentan was discontinued early because of elevated levels of liver enzymes and was replaced by the ENABLE trial that used a lower dose of bosentan. Neither trial reported an improvement in outcomes, and an excess of adverse effects was reported in the active treatment group in both trials. Enrasentan in the ENCOR study and darusentan in the EARTH study were similarly unsuccessful (all three studies have been reviewed previously33). Only the EARTH study was fully published in a timely fashion34, which limited the lessons that could be learned from this large body of work — a situation that is clearly disappointing given the effort that went into running the studies, together with the commitment from the patients enrolled32. In the current era of clinical research, we believe that the trial data should be made available promptly, both to protect patients and to indicate potential ways forward.\nA trial was undertaken with bosentan in a subgroup of patients with CHF and secondary pulmonary hypertension, which addressed an important unanswered question, but bosentan did not affect haemodynamic variables and was associated with more frequent adverse effects requiring drug discontinuation35. These studies were all in patients with CHF and reduced ejection fraction, but one study was undertaken with the ETA-selective agent sitaxentan in patients with preserved ejection fraction (>50%)36. This blinded, randomized, controlled trial compared sitaxentan (100 mg daily) and placebo in 192 patients allocated 2:1 over 24 weeks of follow-up and showed that active treatment significantly increased exercise tolerance, with no more adverse effects than\nplacebo, but did not improve secondary end points such as left ventricular mass or diastolic function36.\nThe story in acute heart failure (AHF) has been similarly disappointing. Initial small studies with a range of ERAs37 suggested a haemodynamic benefit and resulted in the RITZ programme of studies with tezosentan. RITZ-1 and RITZ-2 focused on early symptoms and haemodynamics, respectively, whereas RITZ-4 (ref.38) and RITZ-5 (ref.39) focused on effectiveness in patients with acute coronary syndromes and pulmonary oedema, respectively. In each case, the study showed no benefit except, perhaps unsurprisingly, RITZ-2, which addressed and confirmed the haemodynamic changes (reviewed previously33). These trials were followed by two concurrent, identical large trials (the VERITAS programme) undertaken in a total of >1,400 patients with two of the following criteria: elevated plasma concentrations of B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide, pulmonary oedema on physical examination, radiological evidence of pulmonary congestion or oedema, or left ventricular systolic dysfunction40. In VERITAS, which compared tezosentan (5 mg/h for 30 min followed by 1 mg/h for 24–72 h; n = 730) and matched placebo (n = 718), no improvement was observed in symptoms of dyspnoea, worsening heart failure or mortality.\nThe development of ERAs for heart failure treatment has provided some lessons, not least the disconnect (also found for other drug classes) between the haemodynamic improvements observed in phase I–II studies and the patient-based outcomes of dyspnoea, hospitalizations and deaths in phase III studies41. Other important issues associated with some of the first-generation ERAs\nTable 1 | Effects of ET-1 on vascular smooth muscle\nTarget action receptor\nHeart\nCoronary vasculature Vasoconstriction ETA (ETB)\nVasodilatation ETB Cardiomyocyte Inotropy ETA (ETB)\nLung"
    }, {
      "heading" : "Pulmonary artery Vasoconstriction ETA and ETB",
      "text" : "Vasodilatation ETB\nKidney\nRenal artery Vasoconstriction ETA Vasodilatation ETB\nAfferent arteriole Vasoconstriction ETA and ETB Efferent arteriole Vasoconstriction ETA\nVasodilatation ETB Cortical vasculature Vasoconstriction ETA Medullary vasculature Vasodilatation ETB Mesangial cell Contraction ETA Brain\nCerebral vasculature Vasoconstriction ETA Vasodilatation ETB\nET-1, endothelin 1; ETA, endothelin receptor type A ; ETB, endothelin receptor type B.\nNature reviews | Cardiology\nare the high incidence of hypotension and acute kidney injury (AKI), linked to systemic vasodilatation, and the changes in liver enzyme levels. In addition, whether lower drug doses might improve the balance of benefit to harm remains unclear42. Further clinical trials with ERAs in either AHF or CHF seem unlikely given the lack of clinical benefit and possible harm of fluid retention (although this limitation has been effectively mitigated with the use of a diuretic in the hypertension trials). Nevertheless, an opportunity was potentially missed to gain valuable information from the unpublished early studies of ERAs in CHF. Moreover, no outcome studies have been undertaken with highly selective ETA antagonists in patients with heart failure with reduced ejection fraction (BQ-123 has been used in some animal studies and in proof-of-principle studies in humans6,29), and treatment of heart failure with preserved ejection fraction remains a potentially promising avenue of research."
    }, {
      "heading" : "Pulmonary arterial hypertension",
      "text" : "PAH mostly affects young women and, if untreated, most patients die within 2–3 years of diagnosis43. A sustained rise in pulmonary arterial pressure owing to increases in pulmonary vascular resistance (PVR), leads to dys pnoea, fatigue, chest pain and syncope. Plasma ET-1 level is increased in animal models and patients with PAH. This increase correlates with markers of severity, such as raised PVR and right atrial pressure, and poor outcomes44. The source of this increased ET-1 level is unclear and might be a reflection of either increased production of ETB45 or reduced ETB-mediated clearance46. Since their introduction almost 2 decades ago, dual and selective ERAs have emerged as important treatments for PAH47. ETA-mediated effects are likely to contribute to disease progression, and so their antagonism might be essential in treating PAH. The role of ETB in PAH is less clear. Whereas some transgenic animal and antago nist studies\nsuggest a net vasodilatory (and therefore protective) role for pulmonary ETB in PAH48–51, other studies support a vasoconstrictor role for pulmonary ETB (ref.52). Therefore, combined ETA and ETB blockade might be required for the complete inhibition of ET-1-induced vasoconstriction in PAH. Interestingly, clinical data suggest that ETA-selective agents are more effective when combined with a phosphodiesterase type 5 inhibitor than either drug alone53. This finding has been attributed to ET-1 activating endothelial ETB to release nitric oxide, the effect of which is amplified by phosphodiesterase type 5 inhibition, and supports the use of selective ERAs in PAH.\nCurrently, three ERAs are licensed for the treatment of PAH: the mixed ETA/ETB antagonist bosentan and the ETA-selective antagonists ambrisentan and macitentan. These drugs have been investigated in a number of clinical trials for PAH54. Bosentan (given at a dose of 125 mg twice daily) improves symptoms, exercise tolerance, functional status and time to clinical worsening in patients with PAH47, even in those with mild symptoms55. However, no data show a reduction in mortality. The SERAPHIN study56, which investigated the efficacy of macitentan, was a landmark study in PAH because, unlike previous studies, this study included a large number of patients (n = 742), had a >2-year treatment period and had a composite primary end point of morbidity and mortality (as opposed to the standard surrogate end point of 6-min walking distance). Macitentan reduced the primary end point, although this result was due to a reduction in worsening of PAH; no reduction in all-cause or PAH-related mortality was observed56. Ambrisentan was assessed in the ARIES studies57 and, similar to bosentan, improved symptoms, functional status and quality of life compared with placebo. Overall, ERA therapy is considered first-line treatment for many patients with PAH.\nWith respect to the clinical studies with ERAs in PAH, no data are available on lung fibrosis. Animal studies show that overexpression of ET-1 leads to inflammation and fibrosis, especially in the lungs58, and that these effects are mediated by both ETA and ETB (ref.59). However, transgenic animal studies support a protective role for ETB (ref.60), and a direct comparison of selective ETA, selective ETB and dual ETA–ETB antagonism showed that only dual and selective ETA antagonism prevented pulmonary arterial pressure elevation and structural abnormalities61. Of note, dual receptor blockade provided no additional benefit to that with selective ETA antagonism, whereas isolated ETB blockade aggravated pathological changes. Therefore, in PAH, whereas blockade of both ETA and ETB might be necessary in terms of haemodynamics (because of the upregulation of pulmonary vasoconstrictor ETB), the structural changes are predominantly driven by ETA, and so antagonism of this receptor would seem to be necessary, with little added benefit, but no harm, associated with additional ETB blockade. Currently, no studies have addressed this assumption directly."
    }, {
      "heading" : "Kidney disease",
      "text" : "Proteinuric chronic kidney disease. ET-1 has an important role in renal physiology and pathophysiology (fig. 3). Proteinuria is a common feature of CKD, and the degree of proteinuria is closely associated with renal and\nTable 2 | Major actions of endothelin 1\nTarget action receptor\nCardiovascular\nCardiomyocytes Hypertrophy ETA Vascular smooth muscle cells\nVasoconstriction, growth and proliferation ETA\nPulmonary artery Proliferation ETA and ETB Endothelial cells ET-1 clearance ETB Kidney\nCollecting ducts Natriuresis ETB Adrenal\nZona glomerulosa Aldosterone secretion\nETA and ETB\nInflammatory cells\nMacrophages Inflammation and atherosclerosis ETA\nFibroblasts Fibrosis ETA For effects of endothelin 1 (ET-1) on vascular tone, see Table 1. ETA, endothelin receptor type A ; ETB, endothelin receptor type B.\nwww.nature.com/nrcardio\ncardio vascular outcomes62. To date, a number of acute and chronic dosing studies have been conducted using both selective ETA-blocking and dual ETA/ETB-blocking approaches in diabetic and non-diabetic proteinuric CKD63–69. In summary, ERAs reduce proteinuria, an effect that is probably in large part mediated by the systemic and renal haemodynamic effects of these drugs. Additionally, ERAs improve circulating lipid levels and arterial stiffness in CKD70. Importantly, these effects manifest when ERAs are used in addition to standard care with blockers of the renin–angiotensin–aldosterone system. The pivotal SONAR trial71, a randomized, doubleblind, placebo-controlled study using the ETA-selective ERA atrasentan, aimed to recruit >4,000 patients with type 2 diabetes and proteinuria who were already receiving maximum-tolerated doses of inhibitors of the\nrenin–angiotensin–aldosterone system. The primary outcome was time to doubling of serum creatinine level or occurrence of end-stage renal disease (ESRD). Unfortunately, this study was stopped prematurely because fewer end points occurred than had been anticipated but not owing to concerns about safety. This situation might be a problem for future studies in diabetic CKD, where the benefits of sodium/glucose cotransporter 2 (SGLT2) inhibitors have been shown for both cardiovascular and renal end points72. Publication of the findings of the SONAR study is eagerly awaited because, although the trial was stopped prematurely, the results might show benefits of ERAs in CKD. Encouraging results came from the DUET study73, which examined the safety and efficacy of sparsentan, a dual antagonist of ETA and type 1 angiotensin II receptor, in patients with primary focal and segmental glomerulosclerosis, a condition with few therapeutic options. Sparsentan reduced proteinuria to a greater extent than an angiotensin receptor blocker alone and was well tolerated. These positive results are being taken forward in a larger, phase III outcome study74. Retrophin, the company that produces sparsentan, is also planning a study to explore the efficacy of this drug in immunoglobulin A nephropathy, the most common glomerulonephritis worldwide75.\nLumen\nUrine flow\nEndothelial cell of\nperitubular blood vessel\nCollecting duct cell\na\nET B\nET B\nAVP\nET A\nET A\nET-1\nProtein\nFenestrated endothelium\nPodocyte\nPodocyte dedifferentiation ↑ Podocyte\nET-1 production\nFurther podocyte dedifferentiation\nBreakdown of glomerular filtration barrier\n• Altered glomerular haemodynamics • Mesangial cell contraction and proliferation • Glomerulosclerosis\nGlomerular basement membrane\nMacrophage and monocyte activation\nET-1\nIL-6\nIL-1\nTNF ET-1\nTubular lumen\nVasoconstriction\nInterstitium\nPeritubular blood vessel\nTGFβ\nProtein Inflammatory reaction\nFibrosis (glomerulosclerosis and interstitial fibrosis)\nFibroblast proliferation\nIncreased ECM synthesis\nc\nc\nd\nd\nNa+ NO\nH 2 O\nET-1\nET-1\nNatriuresis and diuresis\nb\nb\na\nAfferent arteriole\nEfferent arteriole\nET B ET B ETAETA\nVasoconstriction\nVasodilatation\nVasoconstriction\nVascular or renal origin\n• Altered glomerular haemodynamics • Mesangial cell contraction and proliferation • Glomerulosclerosis\nET-1\nCuboidal epithelial cell\nwww.nature.com/nrcardio\nAlthough most studies have focused on using ERAs in kidney disease, a small study in patients with type 2 diabetes and nephropathy examined the efficacy of the combined ECE and neprilysin inhibitor daglutril76. In this 8-week, double-blind, placebo-controlled, crossover study, patients were optimized on standard therapy with an angiotensin receptor blocker. Daglutril did not reach the primary end point, which was a reduction in albuminuria. However, a reduction occurred in ambulatory BP, with the largest drop in night-time BP (systolic, diastolic and mean). Potential problems exist with this pharma cological approach. Whereas ECE inhibition blocks ET-1 production, neprilysin inhibition decreases its degradation77. No further studies are currently planned using this agent.\nIschaemia–reperfusion injury. AKI is responsible for ~2 million deaths annually worldwide, and this number is increasing78. Renal ischaemia–reperfusion injury (IRI) is a leading cause of AKI79. Importantly, AKI is independently associated with an increased risk of cardiovascular\ndiesease80, and many patients with AKI progress to CKD and even ESRD81, which increases this risk further. Potential mechanisms explaining the transition of AKI to CKD, and indeed CKD progression, include systemic and renal hypertension as well as glomerular and tubular hypertrophy, which all lead to renal fibrosis. ET-1 might contribute to all these processes, and so targeting this system seems a plausible treatment for renal IRI82.\nCurrent data support a role for ET-1 (acting through ETA) in AKI, with upregulation of the system in relevant animal models83,84. Additionally, selective ETA antagonism given before injury prevents many of the short-term effects of IRI84–87. However, no study has examined ERA administration in a therapeutic manner (after the injury) and over a longer period of time to assess the effect on disease progression. ETB also seems to have a protective role after IRI. Data suggest that ETB is downregulated and inactivated early after IRI and that these changes can be prevented with the use of a mineralocorticoid receptor antagonist, which not only preserved renal function but also reduced renal injury88. Interestingly, this protection was lost when concomitant dosing with a selective ETB antagonist was given, which might be due to a loss of ETB-mediated vasodilatation. Therefore, a decline in ETB expression, or indeed its inactivation, after IRI might lead to sustained vasoconstriction and prolongation of the ischaemic period. This hypothesis might explain why ETA antagonism is unsuccessful in preventing the initial injury after IRI, a time when ETB seems to have a more crucial role.\nThese observations should inform future clinical trials in renal IRI in terms of both timing and choice of therapeutic agent. Preserving ETB expression and function with a mineralocorticoid receptor antagonist might be beneficial as a preventive therapy in situations in which IRI is highly likely, such as after cardiothoracic surgery. Alternatively, selective ETA antagonists might be more beneficial for patients with existing AKI to prevent further decline and progression to CKD.\nEnd-stage renal disease. Cardiovascular mortality is highest among patients with ESRD receiving maintenance haemodialysis89. These patients have up to tenfold increases in plasma and tissue ET-1 levels — higher than is found in any other disease state90. This situation most likely represents a combination of increased production and reduced clearance of ET-1. An upregulated endothelin system might contribute to many of the common complications of dialysis, such as systemic and pulmonary hypertension, ischaemic heart disease, heart failure, peripheral vascular disease and stroke. In models of CKD, a selective ETA blockade approach also reduces medial vascular calcification91, a major pathological feature of CKD. Vascular calcification promotes arterial stiffening, which is an independent risk factor for cardiovascular mortality in patients with ESRD92. Although arterial stiffness can be reduced by selective ETA antagonism in pre-dialysis CKD64, no such data are available in ESRD. These sorts of studies could potentially offer a novel therapy in a group of patients for whom few therapeutic interventions have been shown to improve outcome.\n◀\nNature reviews | Cardiology\nFor some patients with ESRD, kidney transplantation is an alternative option to dialysis. Transplantation might improve quality of life but can be associated with both short-term and longer-term complications, including calcineurin inhibitor toxicity and IRI in the early post-transplantation period and hypertension and cardiovascular disease in the longer term. Calcineurin inhibitor toxicity and IRI might lead to AKI with delayed graft function, which might progress to CKD; IRI is also associated with poor graft survival and increased risk of graft rejection93. A role for the endothelin system in the complications associated with kidney transplantation has previously been reviewed, and the case for clinical trials in this area has been highlighted94.\nScleroderma renal crisis. Scleroderma is an autoimmune connective tissue condition characterized by chronic inflammation and fibrosis95. ERAs are licensed for the treatment of digital ulceration in this condition. Renal involvement, secondary to vascular damage and reduced renal blood flow, is common96. Scleroderma renal crisis, characterized by accelerated arterial hypertension with a rapid decline in renal function often requiring dialysis, is a fairly common and life-threatening complication. Patients with scleroderma have raised plasma and tissue concentrations of ET-1 (ref.97).\nThe ZEBRA study98, which has completed recruitment, is designed to explore the safety and efficacy of 1-year dosing with zibotentan (the most selective ETA antagonist available, with no demonstrable ETB-binding affinity99) in 72 patients with scleroderma renal crisis. The primary outcome is the plasma level of soluble vascular cell adhesion protein 1, a measure of renal involvement in scleroderma. The results of this trial are eagerly awaited."
    }, {
      "heading" : "Subarachnoid haemorrhage",
      "text" : "In health, ET-1 does not contribute to cerebral vascular tone100. However, the endothelin system (both the peptide and its receptors) is upregulated after cerebral ischaemia, which might contribute to vascular dysfunction and brain injury101,102. This upregulation occurs in subarachnoid haemorrhage in which, from a clinical perspective, cerebral vasospasm is the only medically treatable cause of disability and death.\nPreclinical data in animal models of subarachnoid haemorrhage suggested potential benefits of ETA-selective antagonists. However, early clinical trials with the use of mixed ERAs were inconclusive103. Later studies with the selective ETA antagonist clazosentan suggested that the drug prevented cerebral vasospasm after subarachnoid haemorrhage, although the clinical outcome remained unchanged104. A meta-analysis published in 2012, which included data from five studies incorporating a total of 2,601 patients, concluded that ERAs do not affect the functional outcome after subarachnoid haemorrhage, even though they reduce vasospasm105. This finding was no different for selective or dual antagonists.\nAt present, ERAs do not have a role in the medical management of subarachnoid haemorrhage, but the\nresults of ongoing studies, perhaps in more defined cohorts using drugs with an improved adverse effect profile, are awaited106. Indeed, Idorsia has announced a phase III registration study (the REACT trial107) to assess clazosentan for the prevention of clinical deterioration owing to vasospasm-related delayed cerebral ischaemia after subarachnoid haemorrhage."
    }, {
      "heading" : "Antiangiogenic therapy and pre-eclampsia",
      "text" : "Inhibition of vascular endothelial growth factor (VEGF) limits angiogenesis and is a therapeutic strategy in many cancers. Pre-eclampsia is characterized by an excess level of the circulating soluble extramembranous part of VEGF receptor 1 (VEGFR1), which sequesters VEGF, leading to its functional deficiency. Both situations are associated with activation of the endothelin system108.\nAntiangiogenic treatment is associated with the development of hypertension and proteinuria109, with thrombotic microangiopathy evident upon renal biopsy110. These adverse effects, seen in ~30% of patients taking these agents, can be treatment-limiting. Animal and human studies have shown a rise in plasma ET-1 levels after VEGF inhibition with the use of a range of agents, suggesting a class effect111,112. A rise in circulating ET-1 level is also a consistent feature in women presenting with pre-eclampsia and is associated with the rise in VEGFR1 level113. In models of pre-eclampsia, BP rises with the development of proteinuria; an increase also occurs in plasma ET-1 levels, with increased expression of prepro-ET-1 and ETA in both the kidneys and the uterus114. On the basis of antagonist studies (using both selective and mixed ERAs), ET-1 clearly has an important and direct role in the pathogenesis of the hypertension and proteinuria seen in pre-eclampsia115,116 and after VEGF inhibition117,118.\nTo date, no clinical studies have been conducted to explore the utility of ERAs in the setting of either VEGF inhibition or pre-eclampsia. The potential use of ERAs together with VEGF inhibition is an attractive option. This approach might not only allow the continuation of disease-modifying therapy but also slow tumour progression because dysregulation of the endothelin system is now recognized to have an important role in the biology of several solid tumours, including breast, colon, lung and ovarian cancers119, which all have VEGF inhibition as a treatment option. One ongoing study (the ENDEAVOUR trial120) is exploring the use of ERAs in VEGF inhibitor-triggered hypertension, and its results are eagerly awaited. ERAs are teratogenic, and so their use in pregnancy, at least in the first trimester, is prohibited. Emerging data suggest that pre-eclampsia is associated with a long-term risk of cardiovascular disease121, and whether ERAs, administered late in pregnancy or in the postpartum period when teratogenic effects should not apply, might reduce this risk remains unexplored."
    }, {
      "heading" : "Conclusions",
      "text" : "The endothelin system has an important role in cardiovascular physiology and pathophysiology, and endothelin receptor antagonism is now an established therapy for PAH and scleroderma digital ulceration. Promise remains for this therapeutic approach in a number of\nwww.nature.com/nrcardio\nclinical areas including treatment-resistant hypertension and in the setting of antiangiogenic therapy for cancer. Further investigation into the potential pleiotropic clinical benefits of endothelin receptor blockade in AKI, CKD and ESRD (especially in those patients receiving maintenance haemodialysis) also now merits consideration. More broadly, an important role for the endothelin system has been demonstrated in the progression of a number of cancers and in chronic pain syndromes6. Most of the studies examining the role of ET-1 in specific types of pain are preclinical and cover a range of diseases, including arthritis, diabetes and sickle cell disease, which are all associated with increased long-term risk of cardiovascular disease. In sickle cell disease, data suggest an important role for the endothelin system in its associated nephropathy, and clinical trials in this area are planned122. Published online xx xx xxxx\n1. Hickey, K. A., Rubanyi, G., Paul, R. J. & Highsmith, R. F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am. J. Physiol. 248, C550–C556 (1985). 2. Yanagisawa, M. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411–415 (1988). 3. Haynes, W. G. & Webb, D. J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344, 852–854 (1994). 4. Haynes, W. G. et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93, 1860–1870 (1996). 5. MacIntyre, I. M. et al. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. Hypertension 55, 1406–1411 (2010). 6. Davenport, P. et al. Endothelin. Pharmacol. Rev. 68, 357–418 (2016). 7. Ge, Y. et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am. J. Physiol. 291, F1274–F1280 (2006). 8. Gupta, R. M. et al. A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression. Cell 170, 522–533 (2017). 9. Boss, C., Bolli, M. H. & Gatfield, J. From bosentan (Tracleer(R)) to macitentan (Opsumit(R)): The medicinal chemistry perspective. Bioorg. Med. Chem. Lett. 26, 3381–3394 (2016). 10. Wei, A. et al. Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J. Am. Heart Assoc. 5, e003896 (2016). 11. Lariviere, R., Day, R. & Schiffrin, E. L. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 21, 916–920 (1993). 12. Li, J. S., Lariviere, R. & Schiffrin, E. L. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 24, 183–188 (1994). 13. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1345–1422 (2017). 14. Krum, H., Viskoper, R. J., Lacourciere, Y., Budde, M. & Charlon, V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N. Engl. J. Med. 338, 784–790 (1998). 15. Nakov, R., Pfarr, E. & Eberle, S. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am. J. Hypertens. 15, 583–589 (2002). 16. Calhoun, D. A. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51, 1403–1419 (2008). 17. Schiffrin, E. L., Deng, L. Y., Sventek, P. & Day, R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J. Hypertens. 15, 57–63 (1997). 18. Weber, M. A. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374, 1423–1431 (2009). 19. Bakris, G. L. et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentanresistant hypertension trial. Hypertension 56, 824–830 (2010). 20. Webb, D. J. DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension 56, 806–807 (2010). 21. Williams, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059–2068 (2015). 22. Iglarz, M. et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 327, 736–745 (2008). 23. Idorsia. Drug discovery & clinical development. idorsia https://www.idorsia.com/documents/com/ fact-sheets-presentations/fs-clinical-development.pdf (2019). 24. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02603809 (2019). 25. Nelson, J. B. et al. Phase 3, randomized, placebocontrolled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118, 5709–5718 (2012). 26. Vercauteren, M. et al. Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention. J. Pharmacol. Exp. Ther. 361, 322–333 (2017). 27. Sakai, S. et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93, 1214–1222 (1996). 28. Sakai, S. et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384, 353–355 (1996). 29. Gray, G. A. & Webb, D. J. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol. Ther. 72, 109–148 (1996). 30. Kiowski, W. et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346, 732–736 (1995). 31. Cowburn, P. J. et al. Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet 352, 201–202 (1998). 32. Kelland, N. F. & Webb, D. J. Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart 93, 2–4 (2007). 33. Battistini, B., Berthiaume, N., Kelland, N. F., Webb, D. J. & Kohan, D. E. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “-sentan” class of drugs. Exp. Biol. Med. (Maywood) 231, 653–695 (2006). 34. Anand, I. et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364, 327–354 (2004). 35. Kaluski, E. et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension – a multi-center randomized study. Cardiology 109, 273–280 (2008). 36. Zile, M. R. et al. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail. 2, 123–130 (2014). 37. Teerlink, J. R. in Acute Heart Failure (eds Mebazaa, A., Gheorghiade, M., Zannad, F. M. & Parrillo, J. E.) 626–638 (Springer, 2008). 38. O’Connor, C. M. et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J. Am. Coll. Cardiol. 41, 1452–1457 (2003). 39. Kaluski, E. et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 41, 204–210 (2003). 40. McMurray, J. J. et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298, 2009–2019 (2007). 41. Vaduganathan, M., Greene, S. J., Ambrosy, A. P., Gheorghiade, M. & Butler, J. The disconnect between phase II and phase III trials of drugs for heart failure. Nat. Rev. Cardiol. 10, 85–97 (2013). 42. Kelland, N. F. & Webb, D. J. Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp. Biol. Med. (Maywood) 231, 696–699 (2006). 43. D’Alonzo, G. E. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115, 343–349 (1991). 44. Motte, S., McEntee, K. & Naeije, R. Endothelin receptor antagonists. Pharmacol. Ther. 110, 386–414 (2006). 45. Dupuis, J., Stewart, D. J., Cernacek, P. & Gosselin, G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94, 1278–1284 (1996). 46. Dupuis, J., Moe, G. W. & Cernacek, P. Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure. Cardiovasc. Res. 39, 609–616 (1998). 47. Rubin, L. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896–903 (2002). 48. Ivy, D. et al. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am. J. Physiol. 280, L1040–L1048 (2001). 49. Muramatsu, M. et al. Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs. Am. J. Physiol. 276, L358–L364 (1999). 50. Ivy, D. D., Parker, T. A. & Abman, S. H. Prolonged endothelin B receptor blockade causes pulmonary hypertension in the ovine fetus. Am. J. Physiol. 279, L758–L765 (2000). 51. Eddahibi, S., Raffestin, B., Clozel, M., Levame, M. & Adnot, S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am. J. Physiol. 268, H828–H835 (1995). 52. Sato, K. et al. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am. J. Physiol. 269, L668–L672 (1995). 53. Galie, N. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med. 373, 834–844 (2015). 54. Thenappan, T., Ormiston, M. L., Ryan, J. J. & Archer, S. L. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 360, j5492 (2018). 55. Galie, N. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371, 2093–2100 (2008). 56. Pulido, T. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 369, 809–818 (2013).\nNature reviews | Cardiology\n57. Galie, N. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010–3019 (2008). 58. Hocher, B. et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. J. Respir. Cell Mol. Biol. 23, 19–26 (2000). 59. Davie, N. et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 165, 398–405 (2002). 60. Nishida, M. et al. Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats. Eur. J. Pharmacol. 496, 159–165 (2004). 61. Nishida, M., Eshiro, K., Okada, Y., Takaoka, M. & Matsumura, Y. Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotalineinduced pulmonary hypertension. J. Cardiovasc. Pharmacol. 44, 187–191 (2004). 62. de Zeeuw, D. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 65, 2309–2320 (2004). 63. Dhaun, N. et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 54, 113–119 (2009). 64. Dhaun, N. et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57, 772–779 (2011). 65. Dhaun, N. et al. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J. Am. Soc. Nephrol. 24, 31–36 (2013). 66. Wenzel, R. R. et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 60, 655–664 (2009). 67. Kohan, D. E. et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol. 22, 763–772 (2011). 68. Dhaun, N. et al. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol. Dial. Transplant. 22, 3228–3234 (2007). 69. de Zeeuw, D. et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 25, 1083–1093 (2014). 70. Czopek, A., Moorhouse, R., Webb, D. J. & Dhaun, N. Therapeutic potential of endothelin receptor antagonism in kidney disease. Am. J. Physiol. 310, R388–R397 (2016). 71. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01858532 (2018). 72. Neuen, B. L. et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation 138, 1537–1550 (2018). 73. Trachtman, H. et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J. Am. Soc. Nephrol. 29, 2745–2754 (2018). 74. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03493685 (2018). 75. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03762850 (2019). 76. Parvanova, A. et al. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebocontrolled trial. Lancet Diabetes Endocrinol. 1, 19–27 (2013). 77. Ferro, C. J., Spratt, J. C., Haynes, W. G. & Webb, D. J. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97, 2323–2330 (1998). 78. Hsu, C. Y. Where is the epidemic in kidney disease? J. Am. Soc. Nephrol. 21, 1607–1611 (2010). 79. Lameire, N. H. et al. Acute kidney injury: an increasing global concern. Lancet 382, 170–179 (2013). 80. Odutayo, A. et al. AKI and long-term risk for cardiovascular events and mortality. J. Am. Soc. Nephrol. 28, 377–387 (2017). 81. Wald, R. et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302, 1179–1185 (2009). 82. Dhaun, N., Goddard, J. & Webb, D. J. The endothelin system and its antagonism in chronic kidney disease. J. Am. Soc. Nephrol. 17, 943–955 (2006). 83. Wilhelm, S. M., Simonson, M. S., Robinson, A. V., Stowe, N. T. & Schulak, J. A. Endothelin up-regulation and localization following renal ischemia and reperfusion. Kidney Int. 55, 1011–1018 (1999). 84. Zager, R. A., Johnson, A. C., Andress, D. & Becker, K. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int. 84, 703–712 (2013). 85. Gellai, M., Jugus, M., Fletcher, T., DeWolf, R. & Nambi, P. Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat. J. Clin. Invest. 93, 900–906 (1994). 86. Huang, C. et al. The effect of endothelin antagonists on renal ischaemia-reperfusion injury and the development of acute renal failure in the rat. Nephrol. Dial. Transplant. 17, 1578–1585 (2002). 87. Forbes, J. M., Leaker, B., Hewitson, T. D., Becker, G. J. & Jones, C. L. Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists. Kidney Int. 55, 198–208 (1999). 88. Barrera-Chimal, J. et al. Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia. J. Am. Soc. Nephrol. 27, 398–404 (2016). 89. de Jager, D. J. et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302, 1782–1789 (2009). 90. Totsune, K. et al. Detection of immunoreactive endothelin in plasma of hemodialysis patients. FEBS Lett. 249, 239–242 (1989). 91. Lariviere, R. et al. Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease. J. Hypertens. 35, 376–384 (2017). 92. Briet, M., Boutouyrie, P., Laurent, S. & London, G. M. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int. 82, 388–400 (2012). 93. Fuquay, R. et al. Renal ischemia-reperfusion injury amplifies the humoral immune response. J. Am. Soc. Nephrol. 24, 1063–1072 (2013). 94. Raina, A., Horn, E. T. & Benza, R. L. The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists. Transplantation 94, 885–893 (2012). 95. Penn, H. et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100, 485–494 (2007). 96. Denton, C. P. Renal manifestations of systemic sclerosis — clinical features and outcome assessment. Rheumatology 47 (Suppl. 5), v54–v56 (2008). 97. Abraham, D. J. et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 151, 831–841 (1997). 98. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02047708 (2017). 99. Morris, C. D. et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br. J. Cancer 92, 2148–2152 (2005). 100. Andresen, J., Shafi, N. I. & Bryan, R. M. Jr. Endothelial influences on cerebrovascular tone. J. Appl. Physiol. 100, 318–327 (2006). 101. Matsuo, Y., Mihara, S., Ninomiya, M. & Fujimoto, M. Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke 32, 2143–2148 (2001). 102. Petrov, T. & Rafols, J. A. Acute alterations of endothelin-1 and iNOS expression and control of the brain microcirculation after head trauma. Neurol. Res. 23, 139–143 (2001). 103. Chow, M., Dumont, A. S. & Kassell, N. F. Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 51, 1333–1341 (2002). 104. Macdonald, R. L., Pluta, R. M. & Zhang, J. H. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat. Clin. Pract. Neurol. 3, 256–263 (2007). 105. Vergouwen, M. D., Algra, A. & Rinkel, G. J. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 43, 2671–2676 (2012). 106. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02560532 (2018). 107. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03585270 (2019). 108. Saleh, L., Danser, J. A. & van den Meiracker, A. H. Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment. Curr. Opin. Nephrol. Hypertens. 25, 94–99 (2016). 109. Lankhorst, S., Kappers, M. H., van Esch, J. H., Danser, A. H. & van den Meiracker, A. H. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J. Hypertens. 31, 444–454 (2013). 110. Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129–1136 (2008). 111. Kappers, M. H. et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56, 675–681 (2010). 112. de Jesus-Gonzalez, N. et al. Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am. J. Hypertens. 25, 1118–1123 (2012). 113. Verdonk, K. et al. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying reninangiotensin-aldosterone system suppression. Hypertension 65, 1316–1323 (2015). 114. Zhou, J. et al. Gestational hypoxia induces preeclampsia-like symptoms via heightened endothelin-1 signaling in pregnant rats. Hypertension 62, 599–607 (2013). 115. Murphy, S. R., LaMarca, B. B., Cockrell, K. & Granger, J. P. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 55, 394–398 (2010). 116. Alexander, B. T. et al. Endothelin type A receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 37, 485–489 (2001). 117. Lankhorst, S. et al. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension 64, 1282–1289 (2014). 118. Kappers, M. H. et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 59, 151–157 (2012). 119. Rosano, L., Spinella, F. & Bagnato, A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 13, 637–651 (2013). 120. US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT03557190 (2018). 121. Bushnell, C. et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 45, 1545–1588 (2014). 122. US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02712346 (2019). Acknowledgements N.D. has research funding from the Medical Research Council to explore the role of the endothelin system in kidney disease (MRC ref: 6152177 I181211-0759). Author contributions Both authors researched data for the article, discussed its content and wrote the manuscript. D.J.W. reviewed and edited the manuscript before submission. Competing interests N.D. has acted as a consultant for Retrophin. D.J.W. is a member of an Independent Data Monitoring Committee for a trial with AbbVie of atrasentan in diabetic renal disease and is the UK Chief Investigator for a trial with Idorsia of aprocitentan in treatment-resistant hypertension. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Reviewer information Nature Reviews Cardiology thanks E. Schiffrin and the other anonymous reviewer(s), for their contribution to the peer review of this work.\nwww.nature.com/nrcardio"
    } ],
    "references" : [ {
      "title" : "Characterization of a coronary vasoconstrictor produced by cultured endothelial cells",
      "author" : [ "K.A. Hickey", "G. Rubanyi", "R.J. Paul", "R.F. Highsmith" ],
      "venue" : "Am. J. Physiol. 248,",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 1985
    }, {
      "title" : "A novel potent vasoconstrictor peptide produced by vascular endothelial cells",
      "author" : [ "M Yanagisawa" ],
      "venue" : "Nature 332,",
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 1988
    }, {
      "title" : "Contribution of endogenous generation of endothelin-1 to basal vascular tone",
      "author" : [ "W.G. Haynes", "D.J. Webb" ],
      "venue" : "Lancet 344,",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 1994
    }, {
      "title" : "Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans",
      "author" : [ "Haynes", "W. G" ],
      "venue" : "Circulation 93,",
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 1996
    }, {
      "title" : "Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men",
      "author" : [ "MacIntyre", "I. M" ],
      "venue" : "Hypertension 55,",
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2010
    }, {
      "title" : "Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention",
      "author" : [ "Y Ge" ],
      "venue" : "Am. J. Physiol. 291,",
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2006
    }, {
      "title" : "A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression",
      "author" : [ "Gupta", "R. M" ],
      "venue" : "Cell 170,",
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2017
    }, {
      "title" : "The medicinal chemistry perspective",
      "author" : [ "C. Boss", "M.H. Bolli", "Gatfield", "J. From bosentan (Tracleer(R)) to macitentan (Opsumit(R" ],
      "venue" : "Bioorg. Med. Chem. Lett. 26, 3381–3394",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials",
      "author" : [ "Wei", "A. et al. Clinical adverse effects of endothelin receptor antagonists" ],
      "venue" : "J. Am. Heart Assoc. 5, e003896",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats",
      "author" : [ "R. Lariviere", "R. Day", "E.L. Schiffrin" ],
      "venue" : "Hypertension 21,",
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 1993
    }, {
      "title" : "Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy",
      "author" : [ "J.S. Li", "R. Lariviere", "E.L. Schiffrin" ],
      "venue" : "Hypertension 24,",
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 1994
    }, {
      "title" : "a systematic analysis for the Global Burden of Disease Study 2016",
      "author" : [ "GBD 2016 Risk Factors Collaborators. Global", "regional", "national comparative risk assessment of 84 behavioural", "environmental", "occupational", "metabolic risks or clusters of risks", "1990-2016" ],
      "venue" : "Lancet 390, 1345–1422",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension",
      "author" : [ "H. Krum", "R.J. Viskoper", "Y. Lacourciere", "M. Budde", "V. Charlon" ],
      "venue" : "N. Engl. J. Med",
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 1998
    }, {
      "title" : "an effective endothelinA receptor antagonist for treatment of hypertension",
      "author" : [ "R. Nakov", "E. Pfarr", "Eberle", "S. Darusentan" ],
      "venue" : "Am. J. Hypertens. 15, 583–589",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "diagnosis, evaluation, and treatment",
      "author" : [ "Calhoun", "D.A. et al. Resistant hypertension" ],
      "venue" : "A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51, 1403–1419",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension",
      "author" : [ "E.L. Schiffrin", "L.Y. Deng", "P. Sventek", "R. Day" ],
      "venue" : "J. Hypertens",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 1997
    }, {
      "title" : "a randomised, double-blind, placebo-controlled trial",
      "author" : [ "Weber", "M.A. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension" ],
      "venue" : "Lancet 374, 1423–1431",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "report of a darusentanresistant hypertension trial",
      "author" : [ "Bakris", "G.L. et al. Divergent results using clinic", "ambulatory blood pressures" ],
      "venue" : "Hypertension 56, 824–830",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension",
      "author" : [ "Webb", "D.J. DORADO" ],
      "venue" : "Hypertension 56, 806–807",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "a randomised, double-blind, crossover trial",
      "author" : [ "Williams", "B. et al. Spironolactone versus placebo", "bisoprolol", "doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2" ],
      "venue" : "Lancet 386, 2059–2068",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist",
      "author" : [ "M Iglarz" ],
      "venue" : "J. Pharmacol. Exp. Ther. 327,",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2008
    }, {
      "title" : "Phase 3, randomized, placebocontrolled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone",
      "author" : [ "Nelson", "J. B" ],
      "venue" : "Cancer 118,",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2012
    }, {
      "title" : "Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention",
      "author" : [ "M Vercauteren" ],
      "venue" : "J. Pharmacol. Exp. Ther. 361,",
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2017
    }, {
      "title" : "Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart",
      "author" : [ "S Sakai" ],
      "venue" : "Circulation 93,",
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 1996
    }, {
      "title" : "Inhibition of myocardial endothelin pathway improves long-term survival in heart failure",
      "author" : [ "S Sakai" ],
      "venue" : "Nature 384,",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 1996
    }, {
      "title" : "The endothelin system and its potential as a therapeutic target in cardiovascular disease",
      "author" : [ "G.A. Gray", "D.J. Webb" ],
      "venue" : "Pharmacol. Ther",
      "citeRegEx" : "29",
      "shortCiteRegEx" : "29",
      "year" : 1996
    }, {
      "title" : "Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure",
      "author" : [ "W Kiowski" ],
      "venue" : "Lancet 346,",
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 1995
    }, {
      "title" : "Short-term haemodynamic effects of BQ-123, a selective endothelin  ETA-receptor antagonist, in chronic heart failure",
      "author" : [ "Cowburn", "P. J" ],
      "venue" : "Lancet 352,",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 1998
    }, {
      "title" : "publication is good for the public health",
      "author" : [ "N.F. Kelland", "Webb", "D.J. Clinical trials of endothelin antagonists in heart failure" ],
      "venue" : "Heart 93, 2–4",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "the novel “-sentan” class of drugs",
      "author" : [ "B. Battistini", "N. Berthiaume", "N.F. Kelland", "D.J. Webb", "Kohan", "D.E. Profile of past", "current clinical trials involving endothelin receptor antagonists" ],
      "venue" : "Exp. Biol. Med. (Maywood) 231, 653–695",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "randomised, double-blind, placebo-controlled trial",
      "author" : [ "Anand", "I. et al. Long-term effects of darusentan on left-ventricular remodelling", "clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH" ],
      "venue" : "Lancet 364, 327–354",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension – a multi-center randomized study",
      "author" : [ "E Kaluski" ],
      "venue" : "Cardiology 109,",
      "citeRegEx" : "35",
      "shortCiteRegEx" : "35",
      "year" : 2008
    }, {
      "title" : "Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction",
      "author" : [ "Zile", "M. R" ],
      "venue" : "JACC Heart Fail",
      "citeRegEx" : "36",
      "shortCiteRegEx" : "36",
      "year" : 2014
    }, {
      "title" : "Acute Heart Failure",
      "author" : [ "J.R. Teerlink" ],
      "venue" : "J. E.)",
      "citeRegEx" : "37",
      "shortCiteRegEx" : "37",
      "year" : 2008
    }, {
      "title" : "results of the Randomized Intravenous TeZosentan Study (RITZ-4)",
      "author" : [ "O’Connor", "C.M. et al. Tezosentan in patients with acute heart failure", "acute coronary syndromes" ],
      "venue" : "J. Am. Coll. Cardiol. 41, 1452–1457",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study",
      "author" : [ "Kaluski", "E. et al. RITZ-5" ],
      "venue" : "J. Am. Coll. Cardiol. 41, 204–210",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "the VERITAS randomized controlled trials",
      "author" : [ "McMurray", "J.J. et al. Effects of tezosentan on symptoms", "clinical outcomes in patients with acute heart failure" ],
      "venue" : "JAMA 298, 2009–2019",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "The disconnect between phase II and phase III trials of drugs for heart failure",
      "author" : [ "M. Vaduganathan", "S.J. Greene", "A.P. Ambrosy", "M. Gheorghiade", "J. Butler" ],
      "venue" : "Nat. Rev. Cardiol",
      "citeRegEx" : "41",
      "shortCiteRegEx" : "41",
      "year" : 2013
    }, {
      "title" : "a question of dose? Exp",
      "author" : [ "N.F. Kelland", "Webb", "D.J. Clinical trials of endothelin antagonists in heart failure" ],
      "venue" : "Biol. Med. (Maywood) 231, 696–699",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Survival in patients with primary pulmonary hypertension",
      "author" : [ "D’Alonzo", "G. E" ],
      "venue" : "Results from a national prospective registry. Ann. Intern. Med",
      "citeRegEx" : "43",
      "shortCiteRegEx" : "43",
      "year" : 1991
    }, {
      "title" : "Endothelin receptor antagonists",
      "author" : [ "S. Motte", "K. McEntee", "R. Naeije" ],
      "venue" : "Pharmacol. Ther. 110,",
      "citeRegEx" : "44",
      "shortCiteRegEx" : "44",
      "year" : 2006
    }, {
      "title" : "Human pulmonary circulation is an important site for both clearance and production of endothelin-1",
      "author" : [ "J. Dupuis", "D.J. Stewart", "P. Cernacek", "G. Gosselin" ],
      "venue" : "Circulation 94,",
      "citeRegEx" : "45",
      "shortCiteRegEx" : "45",
      "year" : 1996
    }, {
      "title" : "Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure",
      "author" : [ "J. Dupuis", "G.W. Moe", "P. Cernacek" ],
      "venue" : "Cardiovasc. Res",
      "citeRegEx" : "46",
      "shortCiteRegEx" : "46",
      "year" : 1998
    }, {
      "title" : "Bosentan therapy for pulmonary arterial hypertension",
      "author" : [ "Rubin", "L. J" ],
      "venue" : "N. Engl. J. Med",
      "citeRegEx" : "47",
      "shortCiteRegEx" : "47",
      "year" : 2002
    }, {
      "title" : "Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction",
      "author" : [ "D Ivy" ],
      "venue" : "Am. J. Physiol. 280,",
      "citeRegEx" : "48",
      "shortCiteRegEx" : "48",
      "year" : 2001
    }, {
      "title" : "Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs",
      "author" : [ "M Muramatsu" ],
      "venue" : "Am. J. Physiol. 276,",
      "citeRegEx" : "49",
      "shortCiteRegEx" : "49",
      "year" : 1999
    }, {
      "title" : "Prolonged endothelin B receptor blockade causes pulmonary hypertension in the ovine fetus",
      "author" : [ "D.D. Ivy", "T.A. Parker", "S.H. Abman" ],
      "venue" : "Am. J. Physiol. 279,",
      "citeRegEx" : "50",
      "shortCiteRegEx" : "50",
      "year" : 2000
    }, {
      "title" : "Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats",
      "author" : [ "S. Eddahibi", "B. Raffestin", "M. Clozel", "M. Levame", "S. Adnot" ],
      "venue" : "Am. J. Physiol. 268,",
      "citeRegEx" : "51",
      "shortCiteRegEx" : "51",
      "year" : 1995
    }, {
      "title" : "Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs",
      "author" : [ "K Sato" ],
      "venue" : "Am. J. Physiol. 269,",
      "citeRegEx" : "52",
      "shortCiteRegEx" : "52",
      "year" : 1995
    }, {
      "title" : "Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension",
      "author" : [ "N Galie" ],
      "venue" : "N. Engl. J. Med. 373,",
      "citeRegEx" : "53",
      "shortCiteRegEx" : "53",
      "year" : 2015
    }, {
      "title" : "pathogenesis and clinical management",
      "author" : [ "T. Thenappan", "M.L. Ormiston", "J.J. Ryan", "Archer", "S.L. Pulmonary arterial hypertension" ],
      "venue" : "BMJ 360, j5492",
      "citeRegEx" : "54",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "a double-blind, randomised controlled trial",
      "author" : [ "Galie", "N. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study" ],
      "venue" : "Lancet 371, 2093–2100",
      "citeRegEx" : "55",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Macitentan and morbidity and mortality in pulmonary arterial hypertension",
      "author" : [ "T Pulido" ],
      "venue" : "N. Engl. J. Med. 369,",
      "citeRegEx" : "56",
      "shortCiteRegEx" : "56",
      "year" : 2013
    }, {
      "title" : "results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2",
      "author" : [ "Galie", "N. et al. Ambrisentan for the treatment of pulmonary arterial hypertension" ],
      "venue" : "Circulation 117, 3010–3019",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice",
      "author" : [ "B Hocher" ],
      "venue" : "Am. J. Respir. Cell Mol. Biol",
      "citeRegEx" : "58",
      "shortCiteRegEx" : "58",
      "year" : 2000
    }, {
      "title" : "ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells",
      "author" : [ "N Davie" ],
      "venue" : "Am. J. Respir. Crit. Care Med",
      "citeRegEx" : "59",
      "shortCiteRegEx" : "59",
      "year" : 2002
    }, {
      "title" : "Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats",
      "author" : [ "M Nishida" ],
      "venue" : "Eur. J. Pharmacol. 496,",
      "citeRegEx" : "60",
      "shortCiteRegEx" : "60",
      "year" : 2004
    }, {
      "title" : "Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotalineinduced pulmonary hypertension",
      "author" : [ "M. Nishida", "K. Eshiro", "Y. Okada", "M. Takaoka", "Y. Matsumura" ],
      "venue" : "J. Cardiovasc. Pharmacol",
      "citeRegEx" : "61",
      "shortCiteRegEx" : "61",
      "year" : 2004
    }, {
      "title" : "lessons from RENAAL",
      "author" : [ "de Zeeuw", "D. et al. Proteinuria", "a target for renoprotection in patients with type 2 diabetic nephropathy" ],
      "venue" : "Kidney Int. 65, 2309–2320",
      "citeRegEx" : "62",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease",
      "author" : [ "N Dhaun" ],
      "venue" : "Hypertension 54,",
      "citeRegEx" : "63",
      "shortCiteRegEx" : "63",
      "year" : 2009
    }, {
      "title" : "Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease",
      "author" : [ "N Dhaun" ],
      "venue" : "Hypertension 57,",
      "citeRegEx" : "64",
      "shortCiteRegEx" : "64",
      "year" : 2011
    }, {
      "title" : "Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD",
      "author" : [ "N Dhaun" ],
      "venue" : "J. Am. Soc. Nephrol",
      "citeRegEx" : "65",
      "shortCiteRegEx" : "65",
      "year" : 2013
    }, {
      "title" : "Avosentan reduces albumin excretion in diabetics with macroalbuminuria",
      "author" : [ "Wenzel", "R. R" ],
      "venue" : "J. Am. Soc. Nephrol",
      "citeRegEx" : "66",
      "shortCiteRegEx" : "66",
      "year" : 2009
    }, {
      "title" : "Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy",
      "author" : [ "Kohan", "D. E" ],
      "venue" : "J. Am. Soc. Nephrol",
      "citeRegEx" : "67",
      "shortCiteRegEx" : "67",
      "year" : 2011
    }, {
      "title" : "Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease",
      "author" : [ "N Dhaun" ],
      "venue" : "Nephrol. Dial. Transplant",
      "citeRegEx" : "68",
      "shortCiteRegEx" : "68",
      "year" : 2007
    }, {
      "title" : "The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy",
      "author" : [ "D de Zeeuw" ],
      "venue" : "J. Am. Soc. Nephrol",
      "citeRegEx" : "69",
      "shortCiteRegEx" : "69",
      "year" : 2014
    }, {
      "title" : "Therapeutic potential of endothelin receptor antagonism in kidney disease",
      "author" : [ "A. Czopek", "R. Moorhouse", "D.J. Webb", "N. Dhaun" ],
      "venue" : "Am. J. Physiol. 310,",
      "citeRegEx" : "70",
      "shortCiteRegEx" : "70",
      "year" : 2016
    }, {
      "title" : "Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function",
      "author" : [ "Neuen", "B. L" ],
      "venue" : "Circulation 138,",
      "citeRegEx" : "72",
      "shortCiteRegEx" : "72",
      "year" : 2018
    }, {
      "title" : "a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS",
      "author" : [ "Trachtman", "H. et al. DUET" ],
      "venue" : "J. Am. Soc. Nephrol. 29, 2745–2754",
      "citeRegEx" : "73",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "a randomised, crossover, double-blind, placebocontrolled trial",
      "author" : [ "Parvanova", "A. et al. Effect on blood pressure of combined inhibition of endothelin-converting enzyme", "neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria" ],
      "venue" : "Lancet Diabetes Endocrinol. 1, 19–27",
      "citeRegEx" : "76",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo",
      "author" : [ "C.J. Ferro", "J.C. Spratt", "W.G. Haynes", "D.J. Webb" ],
      "venue" : "Circulation 97,",
      "citeRegEx" : "77",
      "shortCiteRegEx" : "77",
      "year" : 1998
    }, {
      "title" : "Where is the epidemic in kidney disease",
      "author" : [ "C.Y. Hsu" ],
      "venue" : "J. Am. Soc. Nephrol",
      "citeRegEx" : "78",
      "shortCiteRegEx" : "78",
      "year" : 2010
    }, {
      "title" : "an increasing global concern",
      "author" : [ "Lameire", "N.H. et al. Acute kidney injury" ],
      "venue" : "Lancet 382, 170–179",
      "citeRegEx" : "79",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "AKI and long-term risk for cardiovascular events and mortality",
      "author" : [ "A Odutayo" ],
      "venue" : "J. Am. Soc. Nephrol",
      "citeRegEx" : "80",
      "shortCiteRegEx" : "80",
      "year" : 2017
    }, {
      "title" : "Chronic dialysis and death among survivors of acute kidney injury requiring dialysis",
      "author" : [ "R Wald" ],
      "venue" : "JAMA 302,",
      "citeRegEx" : "81",
      "shortCiteRegEx" : "81",
      "year" : 2009
    }, {
      "title" : "The endothelin system and its antagonism in chronic kidney disease",
      "author" : [ "N. Dhaun", "J. Goddard", "D.J. Webb" ],
      "venue" : "J. Am. Soc. Nephrol",
      "citeRegEx" : "82",
      "shortCiteRegEx" : "82",
      "year" : 2006
    }, {
      "title" : "Endothelin up-regulation and localization following renal ischemia and reperfusion",
      "author" : [ "S.M. Wilhelm", "M.S. Simonson", "A.V. Robinson", "N.T. Stowe", "J.A. Schulak" ],
      "venue" : "Kidney Int",
      "citeRegEx" : "83",
      "shortCiteRegEx" : "83",
      "year" : 1999
    }, {
      "title" : "Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury",
      "author" : [ "R.A. Zager", "A.C. Johnson", "D. Andress", "K. Becker" ],
      "venue" : "Kidney Int",
      "citeRegEx" : "84",
      "shortCiteRegEx" : "84",
      "year" : 2013
    }, {
      "title" : "Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat",
      "author" : [ "M. Gellai", "M. Jugus", "T. Fletcher", "R. DeWolf", "P. Nambi" ],
      "venue" : "J. Clin. Invest",
      "citeRegEx" : "85",
      "shortCiteRegEx" : "85",
      "year" : 1994
    }, {
      "title" : "The effect of endothelin antagonists on renal ischaemia-reperfusion injury and the development of acute renal failure in the rat",
      "author" : [ "C Huang" ],
      "venue" : "Nephrol. Dial. Transplant",
      "citeRegEx" : "86",
      "shortCiteRegEx" : "86",
      "year" : 2002
    }, {
      "title" : "Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists",
      "author" : [ "J.M. Forbes", "B. Leaker", "T.D. Hewitson", "G.J. Becker", "C.L. Jones" ],
      "venue" : "Kidney Int",
      "citeRegEx" : "87",
      "shortCiteRegEx" : "87",
      "year" : 1999
    }, {
      "title" : "Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia",
      "author" : [ "J Barrera-Chimal" ],
      "venue" : "J. Am. Soc. Nephrol",
      "citeRegEx" : "88",
      "shortCiteRegEx" : "88",
      "year" : 2016
    }, {
      "title" : "Cardiovascular and noncardiovascular mortality among patients starting dialysis",
      "author" : [ "de Jager", "D. J" ],
      "venue" : "JAMA 302,",
      "citeRegEx" : "89",
      "shortCiteRegEx" : "89",
      "year" : 2009
    }, {
      "title" : "Detection of immunoreactive endothelin in plasma of hemodialysis patients",
      "author" : [ "K Totsune" ],
      "venue" : "FEBS Lett. 249,",
      "citeRegEx" : "90",
      "shortCiteRegEx" : "90",
      "year" : 1989
    }, {
      "title" : "Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease",
      "author" : [ "R Lariviere" ],
      "venue" : "J. Hypertens",
      "citeRegEx" : "91",
      "shortCiteRegEx" : "91",
      "year" : 2017
    }, {
      "title" : "Arterial stiffness and pulse pressure in CKD and ESRD",
      "author" : [ "M. Briet", "P. Boutouyrie", "S. Laurent", "G.M. London" ],
      "venue" : "Kidney Int",
      "citeRegEx" : "92",
      "shortCiteRegEx" : "92",
      "year" : 2012
    }, {
      "title" : "Renal ischemia-reperfusion injury amplifies the humoral immune response",
      "author" : [ "R Fuquay" ],
      "venue" : "J. Am. Soc. Nephrol",
      "citeRegEx" : "93",
      "shortCiteRegEx" : "93",
      "year" : 2013
    }, {
      "title" : "a potential novel therapeutic role for endothelin receptor antagonists",
      "author" : [ "A. Raina", "E.T. Horn", "Benza", "R.L. The pathophysiology of endothelin in complications after solid organ transplantation" ],
      "venue" : "Transplantation 94, 885–893",
      "citeRegEx" : "94",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "patient characteristics and long-term outcomes",
      "author" : [ "Penn", "H. et al. Scleroderma renal crisis" ],
      "venue" : "QJM 100, 485–494",
      "citeRegEx" : "95",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Renal manifestations of systemic sclerosis — clinical features and outcome assessment",
      "author" : [ "C.P. Denton" ],
      "venue" : "Rheumatology 47 (Suppl. 5),",
      "citeRegEx" : "96",
      "shortCiteRegEx" : "96",
      "year" : 2008
    }, {
      "title" : "Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease",
      "author" : [ "Abraham", "D. J" ],
      "venue" : "Am. J. Pathol",
      "citeRegEx" : "97",
      "shortCiteRegEx" : "97",
      "year" : 1997
    }, {
      "title" : "clinical and pre-clinical evidence",
      "author" : [ "Morris", "C.D. et al. Specific inhibition of the endothelin A receptor with ZD4054" ],
      "venue" : "Br. J. Cancer 92, 2148–2152",
      "citeRegEx" : "99",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Endothelial influences on cerebrovascular tone",
      "author" : [ "J. Andresen", "N.I. Shafi", "Bryan", "R.M. Jr." ],
      "venue" : "J. Appl. Physiol. 100,",
      "citeRegEx" : "100",
      "shortCiteRegEx" : "100",
      "year" : 2006
    }, {
      "title" : "Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats",
      "author" : [ "Y. Matsuo", "S. Mihara", "M. Ninomiya", "M. Fujimoto" ],
      "venue" : "Stroke 32,",
      "citeRegEx" : "101",
      "shortCiteRegEx" : "101",
      "year" : 2001
    }, {
      "title" : "Acute alterations of endothelin-1 and iNOS expression and control of the brain microcirculation after head trauma",
      "author" : [ "T. Petrov", "J.A. Rafols" ],
      "venue" : "Neurol. Res",
      "citeRegEx" : "102",
      "shortCiteRegEx" : "102",
      "year" : 2001
    }, {
      "title" : "an update",
      "author" : [ "M. Chow", "A.S. Dumont", "Kassell", "N.F. Endothelin receptor antagonists", "cerebral vasospasm" ],
      "venue" : "Neurosurgery 51, 1333–1341",
      "citeRegEx" : "103",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "the emerging revolution",
      "author" : [ "R.L. Macdonald", "R.M. Pluta", "Zhang", "J.H. Cerebral vasospasm after subarachnoid hemorrhage" ],
      "venue" : "Nat. Clin. Pract. Neurol. 3, 256–263",
      "citeRegEx" : "104",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "a systematic review and meta-analysis update",
      "author" : [ "M.D. Vergouwen", "A. Algra", "Rinkel", "G.J. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage" ],
      "venue" : "Stroke 43, 2671–2676",
      "citeRegEx" : "105",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment",
      "author" : [ "L. Saleh", "J.A. Danser", "A.H. van den Meiracker" ],
      "venue" : "Curr. Opin. Nephrol. Hypertens",
      "citeRegEx" : "108",
      "shortCiteRegEx" : "108",
      "year" : 2016
    }, {
      "title" : "evolving role of endothelin-1",
      "author" : [ "S. Lankhorst", "M.H. Kappers", "J.H. van Esch", "A.H. Danser", "van den Meiracker", "A.H. Mechanism of hypertension", "proteinuria during angiogenesis inhibition" ],
      "venue" : "J. Hypertens. 31, 444–454",
      "citeRegEx" : "109",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "VEGF inhibition and renal thrombotic microangiopathy",
      "author" : [ "V Eremina" ],
      "venue" : "N. Engl. J. Med",
      "citeRegEx" : "110",
      "shortCiteRegEx" : "110",
      "year" : 2008
    }, {
      "title" : "Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels",
      "author" : [ "Kappers", "M. H" ],
      "venue" : "Hypertension 56,",
      "citeRegEx" : "111",
      "shortCiteRegEx" : "111",
      "year" : 2010
    }, {
      "title" : "Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1",
      "author" : [ "N de Jesus-Gonzalez" ],
      "venue" : "Am. J. Hypertens",
      "citeRegEx" : "112",
      "shortCiteRegEx" : "112",
      "year" : 2012
    }, {
      "title" : "Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying reninangiotensin-aldosterone system suppression",
      "author" : [ "K Verdonk" ],
      "venue" : "Hypertension 65,",
      "citeRegEx" : "113",
      "shortCiteRegEx" : "113",
      "year" : 2015
    }, {
      "title" : "Gestational hypoxia induces preeclampsia-like symptoms via heightened endothelin-1 signaling in pregnant rats",
      "author" : [ "J Zhou" ],
      "venue" : "Hypertension 62,",
      "citeRegEx" : "114",
      "shortCiteRegEx" : "114",
      "year" : 2013
    }, {
      "title" : "Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats",
      "author" : [ "S.R. Murphy", "B.B. LaMarca", "K. Cockrell", "J.P. Granger" ],
      "venue" : "Hypertension 55,",
      "citeRegEx" : "115",
      "shortCiteRegEx" : "115",
      "year" : 2010
    }, {
      "title" : "Endothelin type A receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure",
      "author" : [ "Alexander", "B. T" ],
      "venue" : "Hypertension 37,",
      "citeRegEx" : "116",
      "shortCiteRegEx" : "116",
      "year" : 2001
    }, {
      "title" : "preclinical study",
      "author" : [ "Lankhorst", "S. et al. Treatment of hypertension", "renal injury induced by the angiogenesis inhibitor sunitinib" ],
      "venue" : "Hypertension 64, 1282–1289",
      "citeRegEx" : "117",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress",
      "author" : [ "Kappers", "M. H" ],
      "venue" : "Hypertension 59,",
      "citeRegEx" : "118",
      "shortCiteRegEx" : "118",
      "year" : 2012
    }, {
      "title" : "biological implications and therapeutic opportunities",
      "author" : [ "L. Rosano", "F. Spinella", "Bagnato", "A. Endothelin 1 in cancer" ],
      "venue" : "Nat. Rev. Cancer 13, 637–651",
      "citeRegEx" : "119",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "a statement for healthcare professionals from the American Heart Association/ American Stroke Association",
      "author" : [ "Bushnell", "C. et al. Guidelines for the prevention of stroke in women" ],
      "venue" : "Stroke 45, 1545–1588",
      "citeRegEx" : "121",
      "shortCiteRegEx" : null,
      "year" : 2014
    } ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "| Cardiovascular disease is a major contributor to global morbidity and mortality and is the common end point of many chronic diseases. The endothelins comprise three structurally similar peptides of 21 amino acids in length. Endothelin 1 (ET-1) and ET-2 activate two G protein-coupled receptors — endothelin receptor type A (ETA) and endothelin receptor type B (ETB) — with equal affinity , whereas ET-3 has a lower affinity for ETA. ET-1 is the most potent vasoconstrictor in the human cardiovascular system and has remarkably long-lasting actions. ET-1 contributes to vasoconstriction, vascular and cardiac hypertrophy, inflammation, and to the development and progression of cardiovascular disease. Endothelin receptor antagonists have revolutionized the treatment of pulmonary arterial hypertension. Clinical trials continue to explore new applications of endothelin receptor antagonists, particularly in treatmentresistant hypertension, chronic kidney disease and patients receiving antiangiogenic therapies. Translational studies have identified important roles for the endothelin isoforms and new therapeutic targets during development, in fluid-electrolyte homeostasis, and in cardiovascular and neuronal function. Novel pharmacological strategies are emerging in the form of smallmolecule epigenetic modulators, biologics (such as monoclonal antibodies for ETB) and possibly signalling pathway-biased agonists and antagonists. 1University of Edinburgh/ British Heart Foundation",
    "creator" : "Springer"
  }
}